Reliable forecasts indicate that there are many new cancer medicines likely to be seeking subsidy on the PBS in addition to expanded indications for already listed agents. In parallel, precision medicine - which provides a greater opportunity to individualise and target therapies are becoming part of standard oncology care.
Many of these newer agents come at much higher cost particularly when used in combination therapy with other within patent medicines. However, the history of the PBS and the PBAC processes that inform what medicines are subsidised on the PBS suggests both have evolved in the past to deal with the cycles of drug discovery.
Professor Andrew Wilson, BMed Sci, MBBS(Hons), PhD, FRACP, FAFPHM
Professor Wilson is the Chair of the Pharmaceutical Benefits Advisory Committee for the Australian Government. He is the Co-director of the Menzies Centre for Health Policy, and Professor of Public Health in the Sydney School of Public Health, University of Sydney and Director of the NHMRC Australian Prevention Partnership Centre. He has specialist qualifications in public health and clinical medicine, and a PhD in epidemiology.
His research interests concern the application of epidemiology to informing decision making in clinical medicine, public health, and health service policy and planning. His papers and reports include aspects of prevention and management of chronic disease, evaluation of the effectiveness and responsiveness of health care and the impact of social and physical environment on health.
Can't attend in person? Register for Webinar